Corcept soars on US FDA nod for first Cushing's drug
This article was originally published in Scrip
Executive Summary
Shares of Corcept Therapeutics climbed more than 60% in after-hours trading on 17 February on word the US FDA gave its blessing to the company's Cushing's syndrome drug Korlym (mifepristone).